Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
2.623
-0.047 (-1.76%)
Nov 21, 2024, 2:07 PM EST - Market open

Company Description

Sutro Biopharma, Inc. operates as a clinical-stage oncology company.

The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+.

Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.

The company’s pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer.

Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC.

The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Sutro Biopharma, Inc.
Sutro Biopharma logo
Country United States
Founded 2003
IPO Date Sep 27, 2018
Industry Biotechnology
Sector Healthcare
Employees 302
CEO William Newell

Contact Details

Address:
111 Oyster Point Boulevard
South San Francisco, California 94080
United States
Phone 650 881 6500
Website sutrobio.com

Stock Details

Ticker Symbol STRO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001382101
CUSIP Number 869367102
ISIN Number US8693671021
Employer ID 45-2441988
SIC Code 2836

Key Executives

Name Position
William J. Newell J.D. Chief Executive Officer and Director
Dr. Hans-Peter Gerber Ph.D. Chief Scientific Officer
Dr. Anne Elizabeth Borgman-Hagey M.D. Chief Medical Officer
Jane Chung R.Ph. President and Chief Operating Officer
Dr. James R. Swartz DSc, Ph.D., Sc.D. Founder
Edward C. Albini M.B.A Chief Financial Officer and Secretary
Dr. Venkatesh Srinivasan Ph.d. Chief Technical Operations Officer
David Pauling J.D., M.A. General Counsel
Linda A. Fitzpatrick Chief People and Communications Officer
Dr. Barbara Leyman Ph.D. Chief Business Development Officer

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024 10-Q Quarterly Report
Nov 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024 8-K Current Report
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 13, 2024 10-Q Quarterly Report